WHAT IS CLAIMED IS:

1. Use of a compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of abscesses or inflammatory nodules resulting from hidradenitis suppurativa, wherein the compound is ruxolitinib, or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the compound is a pharmaceutically acceptable salt of ruxolitinib.

3. The use of claim 2, wherein the pharmaceutically acceptable salt is ruxolitinib phosphate.

4. The use of claim 1, wherein the compound is ruxolitinib free base.

5. The use of any one of claims 1-4, wherein the medicament is to be administered with an additional therapeutic agent.

6. The use of claim 5, wherein the additional therapeutic agent is a corticosteroid.

7. The use of claim 6, wherein the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisone, prednisolone or flumetholone.

8. The use of any one of claims 1-7, wherein the medicament comprising the compound or pharmaceutically acceptable salt is to be administered topically to the skin.

9. The use of any one of claims 1-7, wherein the medicament comprising the compound or pharmaceutically acceptable salt is to be administered orally.

10. The use of any one of claims 1-7, wherein the compound or pharmaceutically acceptable salt is configured to be a topically administered pharmaceutical composition.

11. The use of any one of claims 1-7, wherein the treatment reduces abscesses or inflammatory nodules resulting from hidradenitis suppurativa.

12. The use of claim 11, wherein the treatment reduces abscesses resulting from hidradenitis suppurativa.

13. The use of claim 11, wherein the treatment reduces inflammatory nodules resulting from hidradenitis suppurativa.

14. The use of any one of claims 1-7, wherein the treatment reduces abscesses and inflammatory nodules resulting from hidradenitis suppurativa.